Skip to main content

Utilization of Brodalumab: A Descriptive Analysis

    Basic Details
    Date Posted
    Medical Product

    In this report, we examined uptake of brodalumab in the Sentinel Distributed Database (SDD). This is the first report of an ongoing plan to monitor uptake of brodalumab until sufficient follow-up accrues among treated patients to conduct an inferential analysis examining rates of serious infection, acute myocardial infarction/stroke, and inpatient neutropenia in plaque psoriasis patients initiating brodalumab compared to plaque psoriasis patients initiating non-brodalumab biologics.

    The study period includes data from February 15, 2017 to February 29, 2020. We distributed this request to seven Sentinel Data Partners on January 7, 2021.

    Additional Details
    FDA Center
    Time Period
    February 15, 2017 - February 29, 2020
    Analysis Type
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Sentinel Distributed Database (SDD)